You are here: Industry Insights > Market News > 3 Small Biotechs Big Drugmakers are Making Googly Eyes At

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

3 Small Biotechs Big Drugmakers are Making Googly Eyes At

biospaceJanuary 30, 2018

Tag: biotechs , Googly

Favorites

2018 just might be the best time to be a small biotech -- and own shares of small biotech stocks -- than ever before. Despite a couple of noteworthy deals, last year was relatively quiet on the mergers and acquisitions front in the biopharmaceutical industry. But now, large companies can bring more cash back into the U.S. at lower tax rates thanks to corporate tax reform. And many of them are itching to spend some of that money.

We've already seen several significant acquisitions in just the first few weeks of 2018

Previous:Filing Reveals Kendall Square's InVivo Therapeutics is Burning Through Cash Fast

Next:FDA Formally Rejects Aradigm's Linhaliq, Requests a New Phase III Trial for Reconsideration

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

3 Small Biotechs Big Drugmakers are Making Googly Eyes At | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

3 Small Biotechs Big Drugmakers are Making Googly Eyes At

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

You may like
More>>

3 Small Biotechs Big Drugmakers are Making Googly Eyes At

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

You may likeMore>>

You may like
More>>